Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Editorial

Osteopontin - a biomarker for organ damage in paediatric lupus?

Tracy A Briggs

Author Affiliations

Genetic Medicine, Manchester Academic Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK

Arthritis Research & Therapy 2013, 15:110  doi:10.1186/ar4172


See related research by Rullo et al., http://arthritis-research.com/content/15/1/R18

Published: 8 March 2013

Abstract

A growing body of literature has demonstrated that the multifunctional glycoprotein osteopontin (OPN), has a role in type I interferon (IFN) production and may be involved in systemic lupus erythematosus (SLE) pathogenesis. A recent report has provided further support for this, demonstrating an association between raised baseline circulating plasma osteopontin (cOPN) levels and IFN, and an elevation in cOPN prior to the onset of both increased cumulative disease and end-organ damage. These associations were most marked in paediatric SLE, implying that cOPN may be a useful biomarker of disease activity in childhood lupus.